SCHEMBL28547448

SCHEMBL28547448

Brc1ccc2[nH]cc(Cc3ccccc3)c2c1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 6/20 0.75
MEN1 O00255 2/20 0.65
KMT2A Q03164 2/20 0.65
HTR2A P28223 2/20 0.58
TRPM8 Q7Z2W7 1/20 0.58
CSNK2A1 P68400 1/20 0.56
SLC6A4 P31645 3/20 0.51
HTR1A P08908 3/20 0.51
HTR6 P50406 2/20 0.50
SIGMAR1 Q99720 2/20 0.49
CYP3A4 P08684 1/20 0.49
MAPT P10636 1/20 0.49
AHR P35869 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
ADRA2A P08913 1/20 0.48
DRD2 P14416 1/20 0.48
ADRA2B P18089 1/20 0.48
ADRA2C P18825 1/20 0.48
SLC6A2 P23975 1/20 0.48
ADRA1D P25100 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31744844 0.91 GPR84 (0.67) GPR84MEN1KMT2AHTR2ATRPM8
SCHEMBL31744785 0.90 GPR84 (0.80) GPR84MEN1KMT2AHTR2ATRPM8
SCHEMBL31744847 0.89 GPR84 (0.73) GPR84MEN1KMT2AHTR2ATRPM8
SCHEMBL27929625 0.86 GPR84 (1.00) GPR84MEN1KMT2AHTR2ATRPM8
SCHEMBL3783656 0.86 HTR2A (0.65) GPR84HTR2ATRPM8CSNK2A1SLC6A4
SCHEMBL31744667 0.85 GPR84 (0.83) GPR84MEN1KMT2AHTR2ATRPM8
SCHEMBL31744584 0.84 GPR84 (0.71) GPR84MEN1KMT2AHTR2ATRPM8
SCHEMBL31744639 0.84 GPR84 (0.71) GPR84KMT2AHTR2ATRPM8CSNK2A1
SCHEMBL31744737 0.84 GPR84 (0.71) GPR84MEN1KMT2AHTR2ATRPM8
SCHEMBL3407856 0.84 GPR84 (0.71) GPR84MEN1KMT2AHTR2ATRPM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250382268-A1 METHODS AND COMPOSITIONS FOR SELECTIVELY INHIBITING PATHOGENIC MICROBES CFD RES CORPORATION (US) 2025-12-18 US claimed
US-20250382269-A1 METHODS AND COMPOSITIONS FOR SELECTIVELY INHIBITING PATHOGENIC MICROBES CFD RES CORPORATION (US) 2025-12-18 US disclosed
US-20250382268-A1 METHODS AND COMPOSITIONS FOR SELECTIVELY INHIBITING PATHOGENIC MICROBES CFD RES CORPORATION (US) 2025-12-18 US disclosed
CN-109096272-B Indole hydroxamic acid compound with anti-tumor activity and application thereof 沈阳药科大学 2021-04-02 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250382269-A1 METHODS AND COMPOSITIONS FOR SELECTIVELY INHIBITING PATHOGENIC MICROBES CD14, MIF, NOD2 GPR84 4183/4885MEN1 2402/4885KMT2A 4633/4885
US-20250382268-A1 METHODS AND COMPOSITIONS FOR SELECTIVELY INHIBITING PATHOGENIC MICROBES CD14, MIF, NOD2 GPR84 4183/4885MEN1 2402/4885KMT2A 4633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.